Tissue donation and virus safety: More nucleic acid amplification testing is needed

Transplant Infectious Disease

Volumn 12, Issue 5, 2010, Pages 375-386

  Pruss, A ^a   Caspari, G ^b   Kruger D H ^a   Blumel J ^c   Nubling C M ^c   Gurtler L ^d   Gerlich, W H ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LADR GmbH   (Germany)

^c PAUL EHRLICH INSTITUT   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Allograft; HBV; HCV; HIV; Nucleic acid amplification testing; Tissue bank; Virus safety

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ALLOGRAFT; BLOOD BANK; BLOODSTREAM INFECTION; CARDIOVASCULAR SYSTEM; CORNEA TRANSPLANTATION; COST; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DONOR; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION PREVENTION; MUSCULOSKELETAL SYSTEM; NONHUMAN; NUCLEIC ACID AMPLIFICATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEROLOGY; TISSUE TRANSPLANTATION; TREPONEMA PALLIDUM; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS TRANSMISSION;

BLOOD BANKS; CADAVER; COST-BENEFIT ANALYSIS; HUMANS; LIVING DONORS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; TISSUE AND ORGAN PROCUREMENT; TISSUE TRANSPLANTATION; VIRUS DISEASES; VIRUSES;

EID: 78650501820     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00505.x     Document Type: Review

References (70)

1. Bundesärztekammer. Richtlinien zum Führen einer Knochenbank. Deutsches Ärzteblatt 2001; 98 (15): A1011-A1016.
2. Bundesärztekammer. Richtlinien zum Führen einer Hornhautbank. Deutsches Ärzteblatt 2000; 97 (31-32): A2122-A2124.
3. Paul-Ehrlich-Institut. Bekanntmachung über die Ergebnisse des Stufenplanverfahrens zur Verminderung des Risikos von Hepatitis B-, Hepatitis C- und HIV-Infektionen bei Empfängern von Erythrozytenkonzentraten vom 25.02.1998. BAnz 1998; 53: 3835-3836.
4. Paul-Ehrlich-Institut. Abwehr von Arzneimittelrisiken: Verminderung des Risikos von Hepatitis C-Virus-Kontaminationen in Thrombozytenkonzentraten vom 05.06.1998. BAnz 1998; 114: 8775-8777.
5. Busch MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, Preston S. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000; 40 (2): 143-159.
6. Paul-Ehrlich Institut. Verminderung des Risikos von HIV-1-Infektionen durch zelluläre Blutprodukte und gefrorenes Frischplasma - Anordnung der Testung auf HIV-1-RNA mit NAT. BAnz 2003; 103: 12269.
7. Paul-Ehrlich-Institut. Abwehr von Arzneimittelrisiken; Testung auf Antikörper gegen Hepatitis-B-Core-Antigen (anti-HBc) im Blutspendewesen. BAnz 2006; 109: 4370-4371.
8. Hourfar MK, Jork C, Schottstedt V, et al. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008; 48 (8): 1558-1566.
9. Busch MP. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfus Clin Biol 2004; 11: 26-32.
10. Nübling CM, Seifried E, Weichert W, Löwer J. Human T-cell lymphotropic virus prevalence in German blood donors and 'at-risk' groups. Vox Sang 2001; 81: 204-206.
11. Mitteilungen des Arbeitskreis Blut des Bundesministeriums für Gesundheit. Humane T-Zell lymphotrope Viren Typ 1 und 2 (HTLV-I/-II). Bundesgesundheitsbl 1998; 41: 512-517.
12. Laperche S, Worms B, Pillonel J. Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang 2009; 96 (2): 104-110.
13. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43 (6): 721-729.
14. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351 (8): 760-768.
15. Nübling CM, Unkelbach U, Chudy M, Seitz R. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools. Transfusion 2008; 48: 822-826.
16. Paul-Ehrlich-Institut. Anforderungen an die diagnostische Erprobung von NAT zum Nachweis, zur Bestätigung und zur quantitativen Bestimmung von Markern von HIV-Infektionen sowie von Hepatitis B und C in Proben menschlichen Ursprungs. BAnz 2000; 213: 21805.
17. Challine D, Pellegrin B, Bouvier-Alias M, Rigot P, Laperche L, Pawlotsky JM. HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet 2004; 364: 1611-1612.
18. Zou S, Dodd RY, Stramer SL, Strong DM., Tissue Safety Study Group. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004; 351 (8): 751-759.
19. Brant LJ, Davison KL. Infections detected in English surgical bone and deceased donors (2001-2006) and estimated risk of undetected hepatitis B and hepatitis C. Vox Sang 2008; 95: 272-279.
20. Galea G, Dow BC. Comparison of prevalence rates of microbiological markers between bone/tissue donations and new blood donors in Scotland. Vox Sang 2006; 91: 28-33.
21. Yao F, Seed C, Farrugia A, et al. The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia. Am J Transplant 2007; 7 (12): 2723-2726.
22. Zahariadis G, Plitt SS, O'Brien S, Yi QL, Fan W, Preiksaitis JK. Prevalence and estimated incidence of blood-borne viral pathogen infection in organ and tissue donors from northern Alberta. Am J Transplant 2007; 7 (1): 226-234.
23. Challine D, Roudot-Thoraval F, Sabatier P, et al. Serological viral testing of cadaveric cornea donors. Transplantation 2006; 82 (6): 788-793.
24. Heim A, Wagner D, Rothämel T, Hartmann U, Flik J, Verhagen W. Evaluation of serological screening of cadaveric sera for donor selection for cornea transplantation. J Med Virol 1999; 58 (3): 291-295.
25. Strong DM, Nelson K, Pierce M, Stramer SL. Preventing disease transmission by deceased tissue donors by testing blood for viral nucleic acid. Cell Tiss Bank 2005; 6: 255-262.
26. Schratt HE, Regel G, Kiesewetter B, Tscherne H. HIV-Infektion durch kältekonservierte Knochentransplantate. Unfallchirurg 1996; 9: 679-684.
27. Centers for Disease Control and Prevention (CDC). Transmission of HIV through bone transplantation: case report and public health recommendations. MMWR Morbid Mortal Wkly Rep 1988; 37: 597-599.
28. Simonds RJ, Holmberg SD, Hurwitz RL. Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 1992; 326 (11): 726-732.
29. Clarke JA. HIV transmission and skin grafts. Lancet 1987; i (8539): 983.
30. Li CM, Ho YR, Liu YC. Transmission of human immunodeficiency virus through bone transplantation: a case report. J Formosan Med Assoc 2001; 100: 350-351.
31. Conrad EU, Gretch DR, Obermeyer KR, et al. Transmission of the hepatitis-C virus by tissue transplantation. J Bone Joint Surg Am 1992; 77 (2): 214-224.
32. Eggen BM, Nordbo SA. Transmission of HCV by organ transplantation. N Engl J Med 1992; 326: 411.
33. Pereira BJ, Milford EL, Kirkman RL, et al. Low risk of liver disease after tissue transplantation from donors with HCV. Lancet 1993; 341: 903-904.
34. Trotter JF. Transmission of hepatitis C by implantation of a processed bone graft. A case report. J Bone Joint Surg Am 2003; 85-A (11): 2215-2217.
35. Tugwell BD, Patel PR, Williams IT, et al. Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med 2005; 143 (9): 648-654.
36. Shutkin NM. Homologous-serum hepatitis following the use of refrigerated bone-bank bone. J Bone Joint Surg 1954; 36A: 160-162.
37. Marthy S, Richter M. Human immunodeficiency virus activity in rib allografts. J Oral Maxillofac Surg 1998; 56 (4): 474-476.
38. Cook SD, Salkeld SL, Prewett AB. Simian immunodeficiency virus (human HIV-II) transmission in allograft bone procedures. Spine 1995; 20 (12): 1338-1342.
39. Centers for Disease Control and Prevention (CDC). Update: allograft-associated bacterial infections. MMWR Morbid Mortal Wkly Rep 2002; 51 (10): 207-210.
40. Hoft RH, Pflugfelder SC, Forster RK, Ullman S, Polack FM, Schiff ER. Clinical evidence for hepatitis B transmission resulting from corneal transplantation. Cornea 1997; 16 (2): 132-137.
41. Morris A, Strickett MG, Barratt-Boyes BG. Use of aortic valve allografts from hepatitis B surface antigen-positive donors. Ann Thorac Surg 1990; 49 (5): 802-805.
42. Schwarz A, Hoffman F, L'Age Stehr J, Tegzess AM, Offermann G. Human immunodeficiency virus transmission by organ donation: outcome in cornea and kidney recipients. Transplantation 1987; 44: 21-24.
43. Krajden M, Bishai F, Quan C, et al. Multi-organ donor transmission of hepatitis C virus to five solid organ transplant recipients and lack of transmission to corneal transplant recipients. Clin Diagn Virol 1995; 3 (2): 113-121.
44. Caron MJ, Wilson R. Review of the risk of HIV infection through corneal transplantation in the United States. J Am Optom Assoc 1994; 65 (3): 173-178.
45. Sengler V, Reinhard T, Adams O, Gerlich W, Sundmacher R. Testing of corneoscleral discs and their culture media of seropositive donors for hepatitis B and C virus genomes. Graefes Arch Clin Exper Ophtal 2001; 239: 783-787.
46. Lee HM, Naor J, Alhindi R, et al. Detection of hepatitis C virus in the corneas of seropositive donors. Cornea 2001; 20 (1): 37-40.
47. Glasser DB. Serologic testing of cornea donors. Cornea 1998; 17 (2): 123-128.
48. Robert PY, Adenis JP, Pleyer U. How "safe" is corneal transplantation? A contribution on the risk of HSV-transmission due to corneal transplantation. Klin Monatsbl Augenheilkd 2005; 222 (11): 870-873.
49. Thuret G, Acquart S, Gain P, et al. Ultrastructural demonstration of replicative herpes simplex virus type 1 transmission through corneal graft. Transplantation 2004; 77 (2): 325-326.
50. Bronnert J, Wilde H, Tepsumethanon V, Lumlertdacha B, Hemachudha T. Organ transplantations and rabies transmission. J Travel Med 2007; 14 (3): 177-180.
51. Maddox RA, Belay ED, Curns AT, et al. Creutzfeldt-Jakob disease in recipients of corneal transplants. Cornea 2008; 27 (7): 851-854.
52. File E, Mehra M, Nair S, Dumas-Hicks D, Perrillo R. Allograft transmission of hepatitis C virus infection from infected donors in cardiac transplantation. Transplantation 2003; 76 (7): 1096-1100.
53. Ong JP, Barnes DS, Younossi ZM, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999; 30: 1293-1298.
54. Marelli D, Bresson J, Laks H, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant 2002; 2: 443-447.
55. Pfau PR, Rho R, DeNofrio D, et al. Hepatitis C transmission and infection by orthotopic heart transplantation. J Heart Lung Transplant 2000; 19: 350-354.
56. Yan FM, Chen AS, Hao F, et al. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J Gastroenterol 2000; 6: 805-811.
57. Donoso Mantke O, Meyer R, Prösch S, et al. High prevalence of cardiotropic viruses in myocardial tissue from explanted hearts of heart transplant recipients and heart donors: a 3-year retrospective study from a German patients' pool. J Heart Lung Transplant 2005; 24 (10): 1632-1638.
58. Pruss A, Katthagen BD. Musculoskeletal tissue banks: legal foundations and graft safety. Orthopäde 2008; 37 (8): 749-755.
59. Uhlenhaut C, Dörner T, Pauli G, Pruss A. Effects of lyophilization on the infectivity of enveloped and non-enveloped viruses in bone tissue. Biomaterials 2005; 26 (33): 6558-6564.
60. Solves P, Mirabet V, Alvarez M, et al. Donor screening for hepatitis B virus infection in a cell and tissue bank. Transpl Infect Dis 2008; 10 (6): 391-395.
61. Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol 1999; 107: 186-195.
62. Zanetti AR, Mariano A, Romanò L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379-1384.
63. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008; 48 (6): 1022-1025.
64. Nübling CM, Unger G, Chudy M, Raia S, Löwer J. Sensitivity of HCV core antigen and RNA detection in the early infection phase. Transfusion 2002; 42: 1037-1045.
65. Tuke PW, Grant PR, Waite J, Kitchen AD, Eglin RP, Tedder RS. Hepatitis C virus window-phase infections: closing the window on hepatitis C virus. Transfusion 2008; 48: 594-600.
66. Wilson K. The Krever Commission - 10 years later. CMAJ 2007; 177 (11): 1387-1379.
67. Flören M, Kappe T, Reichel H. Analysis of the effectiveness of an internal hospital bone bank. Orthopäde 2007; 36: 667-72.
68. Komiya Y, Katayama K, Yugi H, et al. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008; 48 (2): 286-294.
69. Österreichisches Bundesinstitut für Gesundheitswesen (ÖBIG) und Bundesministerium für soziale Sicherheit und Generationen: Richtlinien für Homograft-Banken. ÖBIG, April 2002.
70. Pruss A, Caspari G, Krüger DH, et al. Nukleinsäure-Amplifikationstests für HIV, HBV und HCV bei Gewebespendern: Sinnvoll oder überflüssig? Transfus Med Hemother 2008; 35 (6): 421-430.